JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Language

྾

Home
Applications
Targets
Kinases
TK:Tyrosine kinase
tarloxotinib , Epidermal growth factor receptor inhibitor, CAS No.1636938-13-0, Epidermal growth factor receptor inhibitor

tarloxotinib , Epidermal growth factor receptor inhibitor, CAS No.1636938-13-0, Epidermal growth factor receptor inhibitor

Item Number

T614334

Grouped product items
SKU	Size	Availability	Price	Qty
T614334-5mg	5mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$674.90
T614334-25mg	25mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$2,020.90

View related series

Basic Description

Synonyms	TH-4000 \| GTPL9409 \| SCHEMBL19733352 \| Tarloxotinib ion \| Tarloxotinib cation \| TARLOXOTINIB [WHO-DD] \| UNII-H8768UL06V \| 1636938-13-0 \| Tarloxotinib \| [(E)-4-[[4-(3-bromo-4-chloroanilino)pyrido[3,4-d]pyrimidin-6-yl]amino]-4-oxobut-2-enyl]-dimethyl-[(3-me
Specifications & Purity	Moligand™
Grade	Moligand™
Action Type	INHIBITOR
Mechanism of action	Epidermal growth factor receptor inhibitor

ALogP	3.3

IUPAC Name	[(E)-4-[[4-(3-bromo-4-chloroanilino)pyrido[3,4-d]pyrimidin-6-yl]amino]-4-oxobut-2-enyl]-dimethyl-[(3-methyl-5-nitroimidazol-4-yl)methyl]azanium
INCHI	InChI=1S/C24H23BrClN9O3/c1-33-14-30-24(34(37)38)20(33)12-35(2,3)8-4-5-22(36)32-21-10-16-19(11-27-21)28-13-29-23(16)31-15-6-7-18(26)17(25)9-15/h4-7,9-11,13-14H,8,12H2,1-3H3,(H-,27,28,29,31,32,36)/p+1/b5-4+
InChi Key	MUJMYVFVAWFUJL-SNAWJCMRSA-O
Canonical SMILES	O=C(Nc1ncc2c(c1)c(ncn2)Nc1ccc(c(c1)Br)Cl)/C=C/C[N+](Cc1n(C)cnc1[N+](=O)[O-])(C)C
Isomeric SMILES	CN1C=NC(=C1C[N+](C)(C)C/C=C/C(=O)NC2=NC=C3C(=C2)C(=NC=N3)NC4=CC(=C(C=C4)Cl)Br)[N+](=O)[O-]
PubChem CID	51038316
Molecular Weight	601.9

C of A & Other Certificates(BSE/TSE, COO):

Analytical Chart:

1. Phillips RM. (2016) Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs.. Cancer Chemother Pharmacol, 77 (3): (441-57). [PMID:26811177] [10.1021/op500134e]

Determine the necessary mass, volume, or concentration for preparing a solution.

Determine the dilution needed to prepare a stock solution.